Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26118160 | 1.00 | BTK (0.32) | BTKKRAS | |
| SCHEMBL26115837 | 0.95 | KRAS (0.30) | KRAS | |
| SCHEMBL30587267 | 0.94 | BTK (0.31) | BTK | |
| SCHEMBL26117746 | 0.94 | BTK (0.31) | BTK | |
| SCHEMBL26535299 | 0.91 | BTK (0.31) | BTK | |
| SCHEMBL30776278 | 0.91 | BTK (0.31) | BTK | |
| SCHEMBL30776337 | 0.90 | GPR119 (0.30) | — | |
| SCHEMBL26535578 | 0.90 | GPR119 (0.30) | — | |
| SCHEMBL27084192 | 0.90 | MEN1 (0.30) | — | |
| SCHEMBL30587280 | 0.90 | BTK (0.31) | BTKKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119095853-A | KRAS inhibitors | 伊莱利利公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | BTK 176/4885KRAS 1/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | BTK 176/4885KRAS 1/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | BTK 176/4885KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.